April 10, 2020
Company Name: AnGes Inc.
Presentative: Ei Yamada, President & CEO(Code Number 4563, Mothers of the TSE)
Joint development between AnGes and Osaka university for DNA vaccine targeting novel
Coronavirus (COVID-19)
Listed on the COVID-19 candidate vaccines in WHO (World Health Organization)
This is an announcement that joint development between Osaka University and AnGes for DNA vaccine
targeting novel coronavirus has been listed on the COVID-19 candidate vaccines in WHO (World HealthOrganization). AnGes is working on the vaccine development based on our experience of HGF therapeutic
products commercialization with plasmid DNA production technology.
WHO Website - R&D Blueprint and COVID-19
https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/

Landscape of COVID-19 candidate vaccines as of April 4,2020
https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV4april2020.pdf?ua=1【AnGes- Plasmid DNA manufacturing expertise】
 AnGes has the commercializing experience of HGF therapeutic procucts “Collategene®” with Osaka
university by using Plasmid DNA technology in 2019 in the world’s first. With this expertise, we areworking on the vaccine development shorter in time and higher safety.
【Overview of the development of preventive DNA vaccines against the novel coronavirus, using plasmid
DNA manufacturing technology-Reference information from the press release after March 5】
 Joint development of DNA vaccine against novel coronavirus between AnGes and Osaka University(Department of Clinical Gene Therapy; Department of Health Development and Medicine) based on
the previous achievement of plasmid DNA product.
 The manufacturing process can be established in a shorter period of time with the manufacture ofDNA vaccines, compared with the vaccine with using inactivated viruses (attenuated vaccines) or
the vaccine with using genetically modified virus protein.
 The manufacturing operations will be undertaken by Takara Bio Inc. that possesses manufacturing
technology and facilities of plasmid DNA.
 Daicel is developing an intradermal gene transfer method, using this new administration device, andpromote research with Osaka University (Impulse Science for Medicine; Department of Health
Development and Medicine), aiming at its clinical application.
 Use of this new administration device is expected to increase the efficiency of intradermal genetic
expression and antibody production capability, enabling the development of more efficient DNAvaccines.
 EPS Group supports to proceed the clinical trials rapidly<About DNA vaccine>
DNA vaccines are safe and can be produced in a short time period without using any dangerous
pathogens. By inoculating a circular DNA (plasmid) encoding the protein of the target pathogen, thepathogen protein is produced in the body and immunized against the pathogen. Unlike attenuatedvaccines, DNA vaccines are safe as they have no pathogenicity.

The impact this will have on the full-year consolidated results for this fiscal year is currently being
examined.
AnGes, Inc.
Public Relations & Investor Relations Group
Contact: https://www.anges.co.jp/en/contact/